カテゴリー： FactMR, 世界, 医療/バイオ

世界のマイクロバイオーム治療市場2022-2032：種類別（FMT、マイクロバイオーム医薬品）、用途別（クロストリジウム-ディフィシル感染症、クローン病、炎症性腸疾患、糖尿病）、地域別

【英語タイトル】Microbiome Therapeutics Market Size, Share, Growth & Forecast Analysis, by Type (FMT, and Microbiome Drugs), by Application (C. difficile, Crohn's Disease, Inflammatory Bowel Disease, and Diabetes), & by Region – Forecast to 2022–2032

FactMRが出版した調査資料（FACT22DB061）・商品コード：FACT22DB061
・発行会社（調査会社）：FactMR
・発行日：2022年11月4日
・ページ数：約170
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール
・調査対象地域：グローバル
・産業分野：医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧、印刷不可）USD4,500 ⇒換算￥585,000見積依頼/購入/質問フォーム
Global Sie License（同一拠点内共有可）USD8,500 ⇒換算￥1,105,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
Fact.MR社の本調査レポートは、世界のマイクロバイオーム治療市場について調査・分析し、エグゼクティブサマリー、市場概要、市場背景、市場分析＆予測、エンドユーザー別分析、モダリティ別分析、種類別（FMT、マイクロバイオーム医薬品）分析、用途別（クロストリジウム-ディフィシル感染症、クローン病、炎症性腸疾患、糖尿病、その他）分析、地域別（北米、中南米、ヨーロッパ、東アジア、南アジア、オセアニア、中東・アフリカ）分析、市場構造分析、競争分析、仮定、調査手法などの項目を掲載しています。
・エグゼクティブサマリー
・市場概要
・市場背景
・市場分析＆予測
・世界のマイクロバイオーム治療市場規模：種類別
- FMTの市場規模
- マイクロバイオーム医薬品の市場規模
・世界のマイクロバイオーム治療市場規模：用途別
- クロストリジウム-ディフィシル感染症における市場規模
- クローン病における市場規模
- 炎症性腸疾患における市場規模
- 糖尿病における市場規模
- その他用途における市場規模
・世界のマイクロバイオーム治療市場規模：地域別
- 北米のマイクロバイオーム治療市場規模
- 中南米のマイクロバイオーム治療市場規模
- ヨーロッパのマイクロバイオーム治療市場規模
- 東アジアのマイクロバイオーム治療市場規模
- 南アジアのマイクロバイオーム治療市場規模
- オセアニアのマイクロバイオーム治療市場規模
- 中東・アフリカのマイクロバイオーム治療市場規模
・市場構造分析
・競争分析
・仮定
・調査手法

本調査レポートには、各企業の製品ポートフォリオや主要な戦略、包括的なSWOT分析などを含む企業情報が含まれています。企業のプレゼンスは、すべての著名なプレーヤーのマトリックスを介してマッピングおよび提示されるため、実用的な洞察を読者に提供します。これは市場の状況を慎重に提示し、マイクロバイオーム治療ドメインでの競争レベルを予測するのに役立ちます。
❖ レポートの概要 ❖

Microbiome Therapeutics Market – Scope of Report

A recent study by Fact.MR on the microbiome therapeutics market offers a 10-year forecast for 2022 to 2032. The study analyzes crucial trends that are currently determining the growth of the market. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders as well as emerging players associated with offering microbiome therapeutics.

The study also provides the dynamics responsible for influencing the future status of the microbiome therapeutics market over the forecast period. A detailed assessment of value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report.

A list of prominent companies operating in the microbiome therapeutics market, along with their product portfolios, key strategies and SWOT analysis, enhances the reliability of this comprehensive research study.

Report Summary

The study offers comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales of microbiome therapeutics across the globe.

A comprehensive estimate on the market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of microbiome therapeutics during the forecast period. Price point comparison by region with global average price is also considered in the study.

Analysis on Market Size Evaluation

The market has been analyzed for each segment in terms of value (US$ Mn).

Estimates at global and regional levels for microbiome therapeutics are available in terms of “US$ Mn” for value. A Y-o-Y growth contrast on prominent market segments, along with market attractiveness evaluation, has been incorporated in the report. Furthermore, absolute dollar opportunity analysis of all the segments adds prominence to the report.

Absolute dollar opportunity plays a crucial role in assessing the level of opportunity that a manufacturer/distributor can look to achieve, along with identifying potential resources, considering the sales and distribution perspective in the global microbiome therapeutics market.

Inspected Assessment on Regional Segments

Key sections have been elaborated in the report, which have helped deliver projections on regional markets. These chapters include regional macros (political, economic, and business environment outlook), which are expected to have a momentous influence on the growth of the microbiome therapeutics market during the forecast period.

Country-specific valuation on demand for microbiome therapeutics has been offered for each region, along with market scope estimates and forecasts, price index, and impact analysis of the dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.

Detailed breakup in terms of value & volume for emerging countries has also been included in the report.

In-depth Analysis on Competition

The report sheds light on leading manufacturers of microbiome therapeutics, along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in offering microbiome therapeutics has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits report readers to take preemptive steps in advancing their businesses.

Company profiles have been included in the report, which include essentials such as product portfolios and key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting the market status, and predicting the competition level in the microbiome therapeutics domain.

❖ レポートの目次 ❖

Table of Content
1. Executive Summary

1.1. Global Market Outlook

1.2. Demand-side Trends

1.3. Supply-side Trends

1.4. Technology Roadmap Analysis

1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Market Background

3.1. Market Dynamics

3.1.1. Drivers

3.1.2. Restraints

3.1.3. Opportunity

3.1.4. Trends

3.2. Scenario Forecast

3.2.1. Demand in Optimistic Scenario

3.2.2. Demand in Likely Scenario

3.2.3. Demand in Conservative Scenario

3.3. Opportunity Map Analysis

3.4. Investment Feasibility Matrix

3.5. PESTLE and Porter’s Analysis

3.6. Regulatory Landscape

3.6.1. By Key Regions

3.6.2. By Key Countries

3.7. Regional Parent Market Outlook

4. Global Microbiome Therapeutics Market Analysis 2017-2021 and Forecast, 2022-2032

4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021

4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032

4.2.1. Y-o-Y Growth Trend Analysis

4.2.2. Absolute $ Opportunity Analysis

5. Global Microbiome Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Type

5.1. Introduction / Key Findings

5.2. Historical Market Size Value (US$ Mn) Analysis By Type , 2017-2021

5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Type , 2022-2032

5.3.1. FMT

5.3.2. Microbiome Drugs

5.4. Y-o-Y Growth Trend Analysis By Type , 2017-2021

5.5. Absolute $ Opportunity Analysis By Type , 2022-2032

6. Global Microbiome Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Application

6.1. Introduction / Key Findings

6.2. Historical Market Size Value (US$ Mn) Analysis By Application , 2017-2021

6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Application , 2022-2032

6.3.1. C. difficle

6.3.2. Crohn’s disease

6.3.3. Inflammatory Bowel Disease

6.3.4. Diabetes

6.3.5. Others

6.4. Y-o-Y Growth Trend Analysis By Application , 2017-2021

6.5. Absolute $ Opportunity Analysis By Application , 2022-2032

7. Global Microbiome Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Region

7.1. Introduction

7.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021

7.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032

7.3.1. North America

7.3.2. Latin America

7.3.3. Europe

7.3.4. South Asia

7.3.5. East Asia

7.3.6. Oceania

7.3.7. MEA

7.4. Market Attractiveness Analysis By Region

8. North America Microbiome Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

8.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

8.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

8.2.1. By Country

8.2.1.1. U.S.

8.2.1.2. Canada

8.2.2. By Type

8.2.3. By Application

8.3. Market Attractiveness Analysis

8.3.1. By Country

8.3.2. By Type

8.3.3. By Application

8.4. Key Takeaways

9. Latin America Microbiome Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

9.2.1. By Country

9.2.1.1. Brazil

9.2.1.2. Mexico

9.2.1.3. Rest of Latin America

9.2.2. By Type

9.2.3. By Application

9.3. Market Attractiveness Analysis

9.3.1. By Country

9.3.2. By Type

9.3.3. By Application

9.4. Key Takeaways

10. Europe Microbiome Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

10.2.1. By Country

10.2.1.1. Germany

10.2.1.2. U.K.

10.2.1.3. France

10.2.1.4. Spain

10.2.1.5. Italy

10.2.1.6. Rest of Europe

10.2.2. By Type

10.2.3. By Application

10.3. Market Attractiveness Analysis

10.3.1. By Country

10.3.2. By Type

10.3.3. By Application

10.4. Key Takeaways

11. South Asia Microbiome Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

11.2.1. By Country

11.2.1.1. India

11.2.1.2. Malaysia

11.2.1.3. Singapore

11.2.1.4. Thailand

11.2.1.5. Rest of South Asia

11.2.2. By Type

11.2.3. By Application

11.3. Market Attractiveness Analysis

11.3.1. By Country

11.3.2. By Type

11.3.3. By Application

11.4. Key Takeaways

12. East Asia Microbiome Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

12.2.1. By Country

12.2.1.1. China

12.2.1.2. Japan

12.2.1.3. South Korea

12.2.2. By Type

12.2.3. By Application

12.3. Market Attractiveness Analysis

12.3.1. By Country

12.3.2. By Type

12.3.3. By Application

12.4. Key Takeaways

13. Oceania Microbiome Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

13.2.1. By Country

13.2.1.1. Australia

13.2.1.2. New Zealand

13.2.2. By Type

13.2.3. By Application

13.3. Market Attractiveness Analysis

13.3.1. By Country

13.3.2. By Type

13.3.3. By Application

13.4. Key Takeaways

14. MEA Microbiome Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

14.2.1. By Country

14.2.1.1. GCC Countries

14.2.1.2. South Africa

14.2.1.3. Israel

14.2.1.4. Rest of MEA

14.2.2. By Type

14.2.3. By Application

14.3. Market Attractiveness Analysis

14.3.1. By Country

14.3.2. By Type

14.3.3. By Application

14.4. Key Takeaways

15. Key Countries Microbiome Therapeutics Market Analysis

15.1. U.S.

15.1.1. Pricing Analysis

15.1.2. Market Share Analysis, 2021

15.1.2.1. By Type

15.1.2.2. By Application

15.2. Canada

15.2.1. Pricing Analysis

15.2.2. Market Share Analysis, 2021

15.2.2.1. By Type

15.2.2.2. By Application

15.3. Brazil

15.3.1. Pricing Analysis

15.3.2. Market Share Analysis, 2021

15.3.2.1. By Type

15.3.2.2. By Application

15.4. Mexico

15.4.1. Pricing Analysis

15.4.2. Market Share Analysis, 2021

15.4.2.1. By Type

15.4.2.2. By Application

15.5. Germany

15.5.1. Pricing Analysis

15.5.2. Market Share Analysis, 2021

15.5.2.1. By Type

15.5.2.2. By Application

15.6. U.K.

15.6.1. Pricing Analysis

15.6.2. Market Share Analysis, 2021

15.6.2.1. By Type

15.6.2.2. By Application

15.7. France

15.7.1. Pricing Analysis

15.7.2. Market Share Analysis, 2021

15.7.2.1. By Type

15.7.2.2. By Application

15.8. Spain

15.8.1. Pricing Analysis

15.8.2. Market Share Analysis, 2021

15.8.2.1. By Type

15.8.2.2. By Application

15.9. Italy

15.9.1. Pricing Analysis

15.9.2. Market Share Analysis, 2021

15.9.2.1. By Type

15.9.2.2. By Application

15.10. India

15.10.1. Pricing Analysis

15.10.2. Market Share Analysis, 2021

15.10.2.1. By Type

15.10.2.2. By Application

15.11. Malaysia

15.11.1. Pricing Analysis

15.11.2. Market Share Analysis, 2021

15.11.2.1. By Type

15.11.2.2. By Application

15.12. Singapore

15.12.1. Pricing Analysis

15.12.2. Market Share Analysis, 2021

15.12.2.1. By Type

15.12.2.2. By Application

15.13. Thailand

15.13.1. Pricing Analysis

15.13.2. Market Share Analysis, 2021

15.13.2.1. By Type

15.13.2.2. By Application

15.14. China

15.14.1. Pricing Analysis

15.14.2. Market Share Analysis, 2021

15.14.2.1. By Type

15.14.2.2. By Application

15.15. Japan

15.15.1. Pricing Analysis

15.15.2. Market Share Analysis, 2021

15.15.2.1. By Type

15.15.2.2. By Application

15.16. South Korea

15.16.1. Pricing Analysis

15.16.2. Market Share Analysis, 2021

15.16.2.1. By Type

15.16.2.2. By Application

15.17. Australia

15.17.1. Pricing Analysis

15.17.2. Market Share Analysis, 2021

15.17.2.1. By Type

15.17.2.2. By Application

15.18. New Zealand

15.18.1. Pricing Analysis

15.18.2. Market Share Analysis, 2021

15.18.2.1. By Type

15.18.2.2. By Application

15.19. GCC Countries

15.19.1. Pricing Analysis

15.19.2. Market Share Analysis, 2021

15.19.2.1. By Type

15.19.2.2. By Application

15.20. South Africa

15.20.1. Pricing Analysis

15.20.2. Market Share Analysis, 2021

15.20.2.1. By Type

15.20.2.2. By Application

15.21. Israel

15.21.1. Pricing Analysis

15.21.2. Market Share Analysis, 2021

15.21.2.1. By Type

15.21.2.2. By Application

16. Market Structure Analysis

16.1. Competition Dashboard

16.2. Competition Benchmarking

16.3. Market Share Analysis of Top Players

16.3.1. By Regional

16.3.2. By Type

16.3.3. By Application

17. Competition Analysis

17.1. Competition Deep Dive

17.1.1. OpenBiome

17.1.1.1. Overview

17.1.1.2. Product Portfolio

17.1.1.3. Profitability by Market Segments

17.1.1.4. Sales Footprint

17.1.1.5. Strategy Overview

17.1.1.5.1. Marketing Strategy

17.1.2. Seres Therapeutics Inc.

17.1.2.1. Overview

17.1.2.2. Product Portfolio

17.1.2.3. Profitability by Market Segments

17.1.2.4. Sales Footprint

17.1.2.5. Strategy Overview

17.1.2.5.1. Marketing Strategy

17.1.3. 4D Pharma plc.

17.1.3.1. Overview

17.1.3.2. Product Portfolio

17.1.3.3. Profitability by Market Segments

17.1.3.4. Sales Footprint

17.1.3.5. Strategy Overview

17.1.3.5.1. Marketing Strategy

17.1.4. Locus Biosciences, Inc.

17.1.4.1. Overview

17.1.4.2. Product Portfolio

17.1.4.3. Profitability by Market Segments

17.1.4.4. Sales Footprint

17.1.4.5. Strategy Overview

17.1.4.5.1. Marketing Strategy

17.1.5. Enterome SA

17.1.5.1. Overview

17.1.5.2. Product Portfolio

17.1.5.3. Profitability by Market Segments

17.1.5.4. Sales Footprint

17.1.5.5. Strategy Overview

17.1.5.5.1. Marketing Strategy

17.1.6. Finch Therapeutics Group, Inc.

17.1.6.1. Overview

17.1.6.2. Product Portfolio

17.1.6.3. Profitability by Market Segments

17.1.6.4. Sales Footprint

17.1.6.5. Strategy Overview

17.1.6.5.1. Marketing Strategy

17.1.7. Intralytix, Inc.

17.1.7.1. Overview

17.1.7.2. Product Portfolio

17.1.7.3. Profitability by Market Segments

17.1.7.4. Sales Footprint

17.1.7.5. Strategy Overview

17.1.7.5.1. Marketing Strategy

17.1.8. Microbiotica

17.1.8.1. Overview

17.1.8.2. Product Portfolio

17.1.8.3. Profitability by Market Segments

17.1.8.4. Sales Footprint

17.1.8.5. Strategy Overview

17.1.8.5.1. Marketing Strategy

17.1.9. Second Genome

17.1.9.1. Overview

17.1.9.2. Product Portfolio

17.1.9.3. Profitability by Market Segments

17.1.9.4. Sales Footprint

17.1.9.5. Strategy Overview

17.1.9.5.1. Marketing Strategy

17.1.10. Rebiotix Inc.

17.1.10.1. Overview

17.1.10.2. Product Portfolio

17.1.10.3. Profitability by Market Segments

17.1.10.4. Sales Footprint

17.1.10.5. Strategy Overview

17.1.10.5.1. Marketing Strategy

17.1.11. Vedanta Bioscience, Inc.

17.1.11.1. Overview

17.1.11.2. Product Portfolio

17.1.11.3. Profitability by Market Segments

17.1.11.4. Sales Footprint

17.1.11.5. Strategy Overview

17.1.11.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology



★調査レポート[世界のマイクロバイオーム治療市場2022-2032：種類別（FMT、マイクロバイオーム医薬品）、用途別（クロストリジウム-ディフィシル感染症、クローン病、炎症性腸疾患、糖尿病）、地域別] (コード：FACT22DB061)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のマイクロバイオーム治療市場2022-2032：種類別（FMT、マイクロバイオーム医薬品）、用途別（クロストリジウム-ディフィシル感染症、クローン病、炎症性腸疾患、糖尿病）、地域別]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のマイクロバイオーム治療市場2022-2030：種類別（FMT、マイクロバイオーム医薬品）、用途別（クロストリジウム・ディフィシレ菌、クローン病、炎症性腸疾患、糖尿病）、地域別
    GRV22SP101 / Grand View Research / 2022年8月4日 / Grand View Research社の最新調査レポートによると、世界のマイクロバイオーム治療市場規模は2030年までに973.63百万ドルに達っし、2022年から2030年にかけて年平均31.24％成長すると予測されています。本書では、マイクロバイオーム治療の世界市場を多面的に調査し、調査手法・範囲、エグゼクティブサマリー、産業動向、競争状況、種類別（FMT、マイクロバイオーム医薬品）分析、用途別（クロストリジウム・ディフィシレ菌、クローン病、炎症性腸疾患、糖尿病、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、企業情報など、以下の構成でお届けいたします。なお、本書に掲載されている企業情報には、OpenBiome、Seres Therapeutics Inc.、4D...
  • クロストリジウム・ディフィシル治療の世界市場2021年-2025年
    IRTNTR44655 / Technavio / 2021年7月6日 / テクナビオ社は、クロストリジウム・ディフィシル治療の世界市場規模が2021年～2025年まで年平均5%成長し、253.54百万ドルに達すると予測しています。本市場調査レポートでは、クロストリジウム・ディフィシル治療の世界市場について調査・分析し、エグゼクティブサマリー、市場状況、市場規模、ファイブフォース分析、製品別（広域抗生物質、狭域抗生物質）分析、顧客状況、地域別状況、企業状況、企業分析などの項目を掲載しています。 ・エグゼクティブサマリー ・市場状況 ・市場規模 ・ファイブフォース分析...
  • 世界のカプセル内視鏡システム市場2022-2027：製品別（小腸、食道、結腸カプセル内視鏡検査システム）、用途別（OGIB、クローン病、小腸腫瘍、その他）、エンドユーザー別、地域別
    FACT22DE003 / FactMR / 2022年8月25日 / Fact.MR社は、世界のカプセル内視鏡システム市場について調査・分析し、エグゼクティブサマリー、市場動向、市場リスク・動向分析、市場背景・基礎データポイント、市場の需要分析・予測、用途別（OGIB（原因不明消化管出血）、クローン病、小腸腫瘍、その他）分析、製品別（小腸カプセル、食道カプセル、コロンカプセル）分析、エンドユーザー別（病院、外来手術センター、その他）分析、地域別（北米、中南米、ヨーロッパ、東アジア、南アジア・オセアニア、中東・アフリカ）分析、市場構造分析、競合分析、仮定、調査手法などの項目を掲載しています。 ・エグゼクティブサマリー ・市場動向 ・市場リスク・動向分析 ・市場背景・基礎データポイント...
  • 炎症性腸疾患（胃腸）：治療薬開発動向2021
    GMDHC13113IDBOD / Global Markets Direct / 2021年4月 / 炎症性腸疾患（胃腸）- 治療薬開発動向2021 概要 本調査レポートでは炎症性腸疾患（胃腸）治療薬パイプライン状況の概要を掲載しております。 本書では開発段階別分析、創薬ターゲット別分析、作用機序（MoA）別分析、投与経路（RoA）別分析、分子タイプ別分析を含め、炎症性腸疾患（胃腸）治療薬開発に基づく包括的な情報を掲載しております。...
  • クロストリジウム・ディフィシル毒素B：治療薬開発動向2021
    GMDHC4060TDBOD / Global Markets Direct / 2021年4月 / クロストリジウム・ディフィシル毒素B- 治療薬開発動向2021 概要 本調査レポートではクロストリジウム・ディフィシル毒素Bをターゲットとした治療薬パイプラインについて深く分析しており、疾患別分析、開発段階別分析、作用機序（MoA）別分析、投与経路（RoA）別分析、分子タイプ別分析を含めた包括的な情報を掲載しております。 本書はまた、治療薬の記述的薬理作用、完全な研究開発の歴史、最新ニュース＆プレスリリースをカバーしています。...

    • ◆H&Iグローバルリサーチのお客様（例）◆